Review
Copyright ©2012 Baishideng.
World J Transplant. Oct 24, 2012; 2(5): 74-83
Published online Oct 24, 2012. doi: 10.5500/wjt.v2.i5.74
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Calcineurin inhibitor and malignancies. CNI: Calcineurin inhibitor; IL: Interleukin; TGF: Transforming growth factor; VEGF: Vascular endothelial growth factor; EBV: Epstein-Barr virus.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Rapamycins and malignancies. PI3K: Phosphoinositide 3-kinase; mTOR: Mammalian target of rapamycin; IL: Interleukin; VEGF: Vascular endothelial growth factor.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Growth factors and mammalian target of rapamycin pathways. PI3K: Phosphoinositide 3-kinase; mTOR: Mammalian target of rapamycin; IGF: Insulin like growth factor; EGF: Epidermal growth factor; TGF: Transforming growth factor; VEGF: Vascular endothelial growth factor; ER: Estrogen receptor; TSC: Tuberous sclerosis complex.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Mammalian target of rapamycin pathway is deregulated by mutations in cancer. PI3K: Phosphoinositide 3-kinase; mTOR: Mammalian target of rapamycin; IGF: Insulin like growth factor; EGF: Epidermal growth factor; VEGF: Vascular endothelial growth factor; ER: Estrogen receptor; TSC: Tuberous sclerosis complex.